News
-
-
PRESS RELEASE
While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles
NanoViricides, Inc. provides an update on its Measles Drug Treatment Program, introducing NV-387 as a potential treatment for Measles outbreak amid rising cases globally -
-
-
PRESS RELEASE
The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon
NanoViricides, Inc. announces Phase II Clinical Trial of NV-387 Oral Gummies for Ebola viruses led by Prof. Patrick Katoto in DRC. Trial response to growing Bundibugyo outbreak -
-
-
PRESS RELEASE
NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
NanoViricides receives regulatory approval to begin Phase II Clinical Trial of NV-387 Oral Gummies as Treatment for Bundibugyo Ebola, leading to urgent need for effective antiviral drugs in DRC outbreak -
-
